Meanwhile, bioinformatics predicted that wogonin could enhance gemcitabine sensitivity of pancreatic cancer by inhibiting AKT2, CCL2, HSP90AA1, PDE5A, and activating PTGS1, BCHE, SERPINB5, CA2, SRC, DGKA, HIF1A, PTGS2, ABCA1, DPYD, AKR1C3. This evidence concerns the gene CCL2 and familial pancreatic carcinoma.